Maze Therapeutics Statistics Share Statistics Maze Therapeutics has 43.8M
shares outstanding. The number of shares has increased by null%
in one year.
Shares Outstanding 43.8M Shares Change (YoY) n/a Shares Change (QoQ) n/a Owned by Institutions (%) 99.99% Shares Floating n/a Failed to Deliver (FTD) Shares 163 FTD / Avg. Volume 0.13%
Short Selling Information The latest short interest is 1.94M, so 4.43% of the outstanding
shares have been sold short.
Short Interest 1.94M Short % of Shares Out 4.43% Short % of Float 5.42% Short Ratio (days to cover) 16.13
Valuation Ratios The PE ratio is 13.37 and the forward
PE ratio is -3.83.
Maze Therapeutics's PEG ratio is
-0.13.
PE Ratio 13.37 Forward PE -3.83 PS Ratio 4.17 Forward PS 3.5 PB Ratio -2.24 P/FCF Ratio 9.33 PEG Ratio -0.13
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Maze Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 9.76,
with a Debt / Equity ratio of -0.09.
Current Ratio 9.76 Quick Ratio 9.76 Debt / Equity -0.09 Debt / EBITDA 0.44 Debt / FCF 0.36 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee $1.34M Profits Per Employee $417.85K Employee Count 125 Asset Turnover 0.7 Inventory Turnover n/a
Taxes Income Tax 1.17M Effective Tax Rate 2.19%
Stock Price Statistics The stock price has increased by null% in the
last 52 weeks. The beta is 3.13, so Maze Therapeutics's
price volatility has been higher than the market average.
Beta 3.13 52-Week Price Change n/a 50-Day Moving Average 13.89 200-Day Moving Average n/a Relative Strength Index (RSI) 39.32 Average Volume (20 Days) 123,117
Income Statement In the last 12 months, Maze Therapeutics had revenue of 167.5M
and earned 52.23M
in profits. Earnings per share was 0.08.
Revenue 167.5M Gross Profit 167.5M Operating Income 57.59M Net Income 52.23M EBITDA 60.88M EBIT 57.59M Earnings Per Share (EPS) 0.08
Full Income Statement Balance Sheet The company has 196.81M in cash and 26.63M in
debt, giving a net cash position of 170.18M.
Cash & Cash Equivalents 196.81M Total Debt 26.63M Net Cash 170.18M Retained Earnings -358.43M Total Assets 332.84M Working Capital 281.09M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was 75.95M
and capital expenditures -1.15M, giving a free cash flow of 74.81M.
Operating Cash Flow 75.95M Capital Expenditures -1.15M Free Cash Flow 74.81M FCF Per Share 1.71
Full Cash Flow Statement Margins Gross margin is 100%, with operating and profit margins of 34.38% and 31.18%.
Gross Margin 100% Operating Margin 34.38% Pretax Margin 31.88% Profit Margin 31.18% EBITDA Margin 36.35% EBIT Margin 34.38% FCF Margin 44.66%
